In comparison, HR-/HER2+ breast cancer patients treated with MK-2206 and neoadjuvant treatment had higher pathological complete response rates compared to patients receiving standard neoadjuvant therapy alone [178]. This evidence concerns the gene ERBB2 and breast cancer.